Savara (NASDAQ:SVRA) Shares Up 4.8%

Savara Inc (NASDAQ:SVRA)’s stock price shot up 4.8% on Wednesday . The stock traded as high as $4.50 and last traded at $4.41. 233,532 shares were traded during mid-day trading, a decline of 81% from the average session volume of 1,211,780 shares. The stock had previously closed at $4.21.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. JMP Securities dropped their price target on shares of Savara from $10.00 to $9.00 and set a “market outperform” rating for the company in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Savara in a research note on Wednesday, August 14th. Oppenheimer upped their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. Guggenheim raised their price objective on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, Evercore ISI decreased their target price on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, May 16th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara has a consensus rating of “Buy” and an average price target of $11.17.

Savara Price Performance

The company has a fifty day moving average of $4.42 and a 200-day moving average of $4.55. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The stock has a market cap of $610.80 million, a PE ratio of -12.27 and a beta of 0.97.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Sell-side analysts expect that Savara Inc will post -0.44 EPS for the current fiscal year.

Institutional Trading of Savara

Hedge funds have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co purchased a new stake in Savara during the 1st quarter worth about $35,000. Choreo LLC acquired a new stake in Savara in the second quarter valued at approximately $59,000. DRW Securities LLC acquired a new position in Savara during the 2nd quarter worth approximately $62,000. Principal Financial Group Inc. increased its position in shares of Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares during the last quarter. Finally, Profund Advisors LLC acquired a new stake in shares of Savara in the 2nd quarter valued at $105,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.